Argireline

Over-the-Counter

Cosmetic Peptides · Anti-Wrinkle

Argireline is a synthetic hexapeptide widely used in cosmetic skincare as a topical alternative to Botox.

What is Argireline?

Argireline is a synthetic hexapeptide widely used in cosmetic skincare as a topical alternative to Botox. It reduces the appearance of wrinkles by inhibiting neurotransmitter release at the neuromuscular junction, decreasing the muscle contractions that cause expression lines.

Also known as: Acetyl Hexapeptide-3, Acetyl Hexapeptide-8

How Does Argireline Work?

Mimics the N-terminal end of SNAP-25, interfering with the SNARE complex that mediates neurotransmitter vesicle fusion. This reduces acetylcholine release at the neuromuscular junction, decreasing muscle contraction intensity and relaxing expression lines — similar to botulinum toxin but with milder, reversible effects.

What is Argireline Used For?

  • Wrinkle reduction
  • Expression line smoothing
  • Anti-aging skincare

Potential Side Effects

  • Skin irritation (rare)
  • Allergic reaction (very rare)

Contraindications

  • Hypersensitivity to ingredients

FDA Legal Status

United States — FDA

Over-the-Counter

Related Peptides

Head-to-head comparisons:

Frequently Asked Questions

Is Argireline as effective as Botox?
Argireline produces milder effects than Botox — studies show 17-30% wrinkle depth reduction vs Botox's 80-90%. However, it's non-invasive, has no injection risks, and works gradually. It's best for prevention and mild lines, not a replacement for Botox in moderate-to-severe wrinkles.
How long does Argireline take to work?
Most studies show visible results within 15-30 days of consistent use. Maximum effects are typically seen at 60 days. Effects are cumulative and reversible — wrinkles return after discontinuation.

Quick Facts

Legal Status (USA)
Over-the-Counter
Evidence Rating
BModerate Evidence (Some Human Data)
Class / Subclass
Cosmetic Peptides / Anti-Wrinkle
Administration
topical
Typical Dosage
5-10% concentration in serums
Brand Names
Argireline
Year Discovered
2002

Last updated: 2026-04-01

Sources & references

Primary sources used for the dosing, mechanism, side-effect, and regulatory claims on this page. Verify time-sensitive information (regulatory status, prescribing details) on the source before relying on it for medical decisions. See our disclaimer.

  1. PubMed PMID 19072641 — peer-reviewed primary literature on Argireline.
  2. FDA Federal Register — official notice record for FDA regulatory actions and Category 1 / 503A bulk-substance updates.